One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Ligases Enzyme Market

[ 英語タイトル ] Ligases Enzyme Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0089207
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 122
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Agilent Technologies Inc.
- ArcticZymes
- Becton, Dickinson and Company
- Merck KGaA
- New England Biolabs
- Promega Corporation
- Takara Bio Inc.
- Thermo Fisher Scientific

[Report Description]

The ligases enzyme market is anticipated to record a CAGR of nearly 5.5% during the forecast period. An increase in R&D investments to develop ligases as targets for therapeutic intervention of cancer is anticipated to drive the market over the forecast period. Post-translational modification of protein is important for maintaining the physiological function. Dysregulation of protein ubiquitination will induce cancer. Ligases and deubiquitinases regulate protein ubiquitination to control the function and stability of protein, thereby developing inhibitors for the prevention of target disease. This results in a growing need for ligases in disease treatment, thereby propelling the market growth.

Furthermore, an increase in the incidence of birth genetic disorders and infectious diseases is expected to drive the market growth as ligases find application in the detection of birth mutations and infectious diseases. For example, as per the World Health Organization, in the United States, sickle cell anemia affects around 72,000 people, most of whose ancestors come from Africa. About 2 million Americans, or 1 in 12 African Americans, carry the sickle cell allele. Rise in research activities for sequencing applications and involvement of ligase enzymes in protein engineering are considered to be the key factors contributing to market growth.

However, high sensitivity of the enzyme to factors, such as DNA concentration, ligase concentration, temperature, and buffer composition , limits its adoption, which may hinder the growth of the ligase enzyme market.

Key Market Trends

Polymerase Chain Reaction Segment Dominates the Market and is Expected to Continue the Same during the Forecast Period

- Polymerase chain reaction (PCR) is expected to dominate of the ligases enzyme market through the forecast period. PCR involves a thermostable ligase to join two probes or other molecules together. This technology has wide-ranging applications in both basic and diagnostic research, such as human genetic testing, forensic sciences, pathogen detection, and infectious disease testing, which act as a high impact rendering factor for this segment’s growth. High prevalence of target diseases and rapid technological advancements, such as the development of high performance and superior qPCR and dPCR systems that demand the high need of ligases, are expected to be the key factors driving the growth.

North America Dominates the Market and is Expected to Continue the Same during the Forecast Period

North America is a prominent market due to the well-established end-user industries, such as molecular biology laboratories, research institutes, and pharmaceuticals companies. High scope for R&D activities in major countries is driving regional growth. The US government has heavily invested in R&D to promote the production of ligases as therapeutics for various genetic disorders, which is expected to propel the regional market over the forecast period.

Asia-Pacific is anticipated to witness lucrative growth over the forecast period. The target population comprising individuals with genetic disorders, such as sickle cell anemia and hemophilia, is on the rise in this region. This provides avenues for players in this vertical to carry out research and develop a novel treatment with regards to disease treatment, thereby, increasing product penetration in the regional verticals.

Competitive Landscape

The ligases enzyme market is moderately competitive and consists of the global as well as local players. Due to the technological advancements, small and mid-sized companies are focusing on market penetration to grab the market share. Some of the companies that are currently present in the market are ArcticZymes, New England Biolabs, Promega Corporation, QIAGEN, and Takara Bio Inc. New product launches, collaborations, mergers, and acquisitions are the key initiatives undertaken by the leading players in this vertical to sustain the competition. For instance, in February 2019, ArcticZymes launched its first ligase enzyme, T4 DNA ligase, which is a widely used enzyme in the ligase family with an aim of growing a synergistic portfolio beyond novel enzyme products.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Birth Genetic Disorders and Infectious Diseases
4.2.2 Advent in Ligases as Therapeutic Interventions of Cancer
4.2.3 Rising Research Activities for Sequencing Applications
4.3 Market Restraints
4.3.1 Risk of High Sensitivity of the Enzyme
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Source
5.1.1 Microorganisms Bacteria Virus Other Microorganisms
5.1.2 Animal
5.1.3 Plant
5.2 By Application
5.2.1 Polymerase Chain Reaction
5.2.2 Cloning
5.2.3 Mutation Detection
5.2.4 Next-generation Sequencing
5.2.5 Drug Target
5.3 By End User
5.3.1 Diagnostic Centers and Hospitals
5.3.2 Research Institutes
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 ArcticZymes
6.1.3 Becton, Dickinson and Company
6.1.4 Merck KGaA
6.1.5 New England Biolabs
6.1.6 Promega Corporation
6.1.7 QIAGEN
6.1.8 Takara Bio Inc.
6.1.9 Thermo Fisher Scientific




Recommended reports